APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biosimilars Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biosimilars Drug Market Outlook and Growth Opportunities 2026

Report ID 173970970421 December 2025219 pages

Choose your research edition.

Industry ResearchBiosimilars Drug Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilars Drug Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Biosimilars Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilars Drug Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilars Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Biosimilars Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biosimilars Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biosimilars Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biosimilars Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biosimilars Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biosimilars Drug market include Sanofi, Qilu Pharmaceutical, Novartis, Eli Lilly, Pfizer, Zhejiang Hisun, Wockhardt, United Laboratory and Tonghua Dongbao, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Biosimilars Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biosimilars Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilars Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Biosimilars Drug market.

Biosimilars Drug Segment by Company

Sanofi

Qilu Pharmaceutical

Novartis

Eli Lilly

Pfizer

Zhejiang Hisun

Wockhardt

United Laboratory

Tonghua Dongbao

Shanghai Henlius

Luye Pharma

Jiangsu Hengrui

Innovent Biologics

Geropharm

Gan&Lee

Dr Reddy’s

Celltrion

Celgen Biopharma

Bio-Thera

Biocon

3SBIO

Biosimilars Drug Segment by Type

Monoclonal Antibodies

Insulin

Others

Biosimilars Drug Segment by Application

Hospital

Retail Pharmacy

Other

Biosimilars Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biosimilars Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Biosimilars Drug key companies, revenue, market share, and recent developments.

3. To split the Biosimilars Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Biosimilars Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biosimilars Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Biosimilars Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilars Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biosimilars Drug industry.

Chapter 3: Detailed analysis of Biosimilars Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Biosimilars Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Biosimilars Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biosimilars Drug Industry Trends Table 2. Biosimilars Drug Industry Drivers Table 3. Biosimilars Drug Industry Opportunities and Challenges Table 4. Biosimilars Drug Industry Restraints Table 5. Global Biosimilars Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biosimilars Drug Revenue Share by Company (2021-2026) Table 7. Global Biosimilars Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Biosimilars Drug Key Company Manufacturing Base & Headquarters Table 9. Global Biosimilars Drug Company, Product Type & Application Table 10. Global Biosimilars Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Biosimilars Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Monoclonal Antibodies Table 15. Significant Companies of Insulin Table 16. Significant Companies of Others Table 17. Global Biosimilars Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Biosimilars Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Biosimilars Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Biosimilars Drug Sales Value Share by Type (2021-2026) Table 21. Global Biosimilars Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Retail Pharmacy Table 24. Significant Companies of Other Table 25. Global Biosimilars Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Biosimilars Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Biosimilars Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Biosimilars Drug Sales Value Share by Application (2021-2026) Table 29. Global Biosimilars Drug Sales Value Share by Application (2027-2032) Table 30. Global Biosimilars Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Biosimilars Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Biosimilars Drug Sales Value Share by Region (2021-2026) Table 33. Global Biosimilars Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Biosimilars Drug Sales Value Share by Region (2027-2032) Table 35. Global Biosimilars Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Biosimilars Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Biosimilars Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Biosimilars Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Biosimilars Drug Sales Value Market Share by Country (2027-2032) Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Biosimilars Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sanofi Biosimilars Drug Product Portfolio Table 44. Sanofi Recent Development Table 45. Qilu Pharmaceutical Company Information Table 46. Qilu Pharmaceutical Business Overview Table 47. Qilu Pharmaceutical Biosimilars Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Qilu Pharmaceutical Biosimilars Drug Product Portfolio Table 49. Qilu Pharmaceutical Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Biosimilars Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novartis Biosimilars Drug Product Portfolio Table 54. Novartis Recent Development Table 55. Eli Lilly Company Information Table 56. Eli Lilly Business Overview Table 57. Eli Lilly Biosimilars Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Eli Lilly Biosimilars Drug Product Portfolio Table 59. Eli Lilly Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer Biosimilars Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Pfizer Biosimilars Drug Product Portfolio Table 64. Pfizer Recent Development Table 65. Zhejiang Hisun Company Information Table 66. Zhejiang Hisun Business Overview Table 67. Zhejiang Hisun Biosimilars Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Zhejiang Hisun Biosimilars Drug Product Portfolio Table 69. Zhejiang Hisun Recent Development Table 70. Wockhardt Company Information Table 71. Wockhardt Business Overview Table 72. Wockhardt Biosimilars Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Wockhardt Biosimilars Drug Product Portfolio Table 74. Wockhardt Recent Development Table 75. United Laboratory Company Information Table 76. United Laboratory Business Overview Table 77. United Laboratory Biosimilars Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. United Laboratory Biosimilars Drug Product Portfolio Table 79. United Laboratory Recent Development Table 80. Tonghua Dongbao Company Information Table 81. Tonghua Dongbao Business Overview Table 82. Tonghua Dongbao Biosimilars Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Tonghua Dongbao Biosimilars Drug Product Portfolio Table 84. Tonghua Dongbao Recent Development Table 85. Shanghai Henlius Company Information Table 86. Shanghai Henlius Business Overview Table 87. Shanghai Henlius Biosimilars Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Shanghai Henlius Biosimilars Drug Product Portfolio Table 89. Shanghai Henlius Recent Development Table 90. Luye Pharma Company Information Table 91. Luye Pharma Business Overview Table 92. Luye Pharma Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Luye Pharma Biosimilars Drug Product Portfolio Table 94. Luye Pharma Recent Development Table 95. Jiangsu Hengrui Company Information Table 96. Jiangsu Hengrui Business Overview Table 97. Jiangsu Hengrui Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Jiangsu Hengrui Biosimilars Drug Product Portfolio Table 99. Jiangsu Hengrui Recent Development Table 100. Innovent Biologics Company Information Table 101. Innovent Biologics Business Overview Table 102. Innovent Biologics Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Innovent Biologics Biosimilars Drug Product Portfolio Table 104. Innovent Biologics Recent Development Table 105. Geropharm Company Information Table 106. Geropharm Business Overview Table 107. Geropharm Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Geropharm Biosimilars Drug Product Portfolio Table 109. Geropharm Recent Development Table 110. Gan&Lee Company Information Table 111. Gan&Lee Business Overview Table 112. Gan&Lee Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Gan&Lee Biosimilars Drug Product Portfolio Table 114. Gan&Lee Recent Development Table 115. Dr Reddy’s Company Information Table 116. Dr Reddy’s Business Overview Table 117. Dr Reddy’s Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Dr Reddy’s Biosimilars Drug Product Portfolio Table 119. Dr Reddy’s Recent Development Table 120. Celltrion Company Information Table 121. Celltrion Business Overview Table 122. Celltrion Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Celltrion Biosimilars Drug Product Portfolio Table 124. Celltrion Recent Development Table 125. Celgen Biopharma Company Information Table 126. Celgen Biopharma Business Overview Table 127. Celgen Biopharma Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Celgen Biopharma Biosimilars Drug Product Portfolio Table 129. Celgen Biopharma Recent Development Table 130. Bio-Thera Company Information Table 131. Bio-Thera Business Overview Table 132. Bio-Thera Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Bio-Thera Biosimilars Drug Product Portfolio Table 134. Bio-Thera Recent Development Table 135. Biocon Company Information Table 136. Biocon Business Overview Table 137. Biocon Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Biocon Biosimilars Drug Product Portfolio Table 139. Biocon Recent Development Table 140. 3SBIO Company Information Table 141. 3SBIO Business Overview Table 142. 3SBIO Biosimilars Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 143. 3SBIO Biosimilars Drug Product Portfolio Table 144. 3SBIO Recent Development Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Biosimilars Drug Product Image Figure 2. Global Biosimilars Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilars Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Monoclonal Antibodies Image Figure 8. Insulin Image Figure 9. Others Image Figure 10. Global Biosimilars Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Biosimilars Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Biosimilars Drug Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Retail Pharmacy Image Figure 15. Other Image Figure 16. Global Biosimilars Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Biosimilars Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Biosimilars Drug Sales Value Share by Application (2021-2032) Figure 19. Global Biosimilars Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Biosimilars Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Biosimilars Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Biosimilars Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Biosimilars Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Biosimilars Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Biosimilars Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Biosimilars Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Biosimilars Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Biosimilars Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Biosimilars Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Biosimilars Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Biosimilars Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Biosimilars Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Biosimilars Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Insulin
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Sanofi
  • Qilu Pharmaceutical
  • Novartis
  • Eli Lilly
  • Pfizer
  • Zhejiang Hisun
  • Wockhardt
  • United Laboratory
  • Tonghua Dongbao
  • Shanghai Henlius
  • Luye Pharma
  • Jiangsu Hengrui
  • Innovent Biologics
  • Geropharm
  • Gan&Lee
  • Dr Reddy’s
  • Celltrion
  • Celgen Biopharma
  • Bio-Thera
  • Biocon
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biosimilars Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biosimilars Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Biosimilars Drug Market Dynamics
  1. 2.1 Biosimilars Drug Industry Trends
  2. 2.2 Biosimilars Drug Industry Drivers
  3. 2.3 Biosimilars Drug Industry Opportunities and Challenges
  4. 2.4 Biosimilars Drug Industry Restraints
3 Biosimilars Drug Market by Company
  1. 3.1 Global Biosimilars Drug Company Revenue Ranking in 2025
  2. 3.2 Global Biosimilars Drug Revenue by Company (2021-2026)
  3. 3.3 Global Biosimilars Drug Company Ranking (2024-2026)
  4. 3.4 Global Biosimilars Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Biosimilars Drug Company Product Type and Application
  6. 3.6 Global Biosimilars Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Biosimilars Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Biosimilars Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Biosimilars Drug Market by Type
  1. 4.1 Biosimilars Drug Type Introduction
  2. 4.1.1 Monoclonal Antibodies
  3. 4.1.2 Insulin
  4. 4.1.3 Others
  5. 4.2 Global Biosimilars Drug Sales Value by Type
  6. 4.2.1 Global Biosimilars Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Biosimilars Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Biosimilars Drug Sales Value Share by Type (2021-2032)
5 Biosimilars Drug Market by Application
  1. 5.1 Biosimilars Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Biosimilars Drug Sales Value by Application
  6. 5.2.1 Global Biosimilars Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biosimilars Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Biosimilars Drug Sales Value Share by Application (2021-2032)
6 Biosimilars Drug Regional Value Analysis
  1. 6.1 Global Biosimilars Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biosimilars Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Biosimilars Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Biosimilars Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biosimilars Drug Sales Value (2021-2032)
  7. 6.3.2 North America Biosimilars Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Biosimilars Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Biosimilars Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Biosimilars Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Biosimilars Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Biosimilars Drug Sales Value (2021-2032)
  16. 6.6.2 South America Biosimilars Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Biosimilars Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Biosimilars Drug Sales Value Share by Country, 2025 VS 2032
7 Biosimilars Drug Country-level Value Analysis
  1. 7.1 Global Biosimilars Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biosimilars Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Biosimilars Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Biosimilars Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Biosimilars Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Biosimilars Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Biosimilars Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Biosimilars Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Biosimilars Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Biosimilars Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Biosimilars Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Biosimilars Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Biosimilars Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Biosimilars Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Biosimilars Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Biosimilars Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Biosimilars Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Biosimilars Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Biosimilars Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Biosimilars Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Biosimilars Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Biosimilars Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Biosimilars Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Biosimilars Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Biosimilars Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Biosimilars Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Biosimilars Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Biosimilars Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Biosimilars Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Biosimilars Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Biosimilars Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Biosimilars Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Biosimilars Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Biosimilars Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Biosimilars Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Biosimilars Drug Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Qilu Pharmaceutical
  8. 8.2.1 Qilu Pharmaceutical Company Information
  9. 8.2.2 Qilu Pharmaceutical Business Overview
  10. 8.2.3 Qilu Pharmaceutical Biosimilars Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Qilu Pharmaceutical Biosimilars Drug Product Portfolio
  12. 8.2.5 Qilu Pharmaceutical Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Biosimilars Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Biosimilars Drug Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Biosimilars Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Biosimilars Drug Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Biosimilars Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Biosimilars Drug Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Zhejiang Hisun
  32. 8.6.1 Zhejiang Hisun Company Information
  33. 8.6.2 Zhejiang Hisun Business Overview
  34. 8.6.3 Zhejiang Hisun Biosimilars Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Zhejiang Hisun Biosimilars Drug Product Portfolio
  36. 8.6.5 Zhejiang Hisun Recent Developments
  37. 8.7 Wockhardt
  38. 8.7.1 Wockhardt Company Information
  39. 8.7.2 Wockhardt Business Overview
  40. 8.7.3 Wockhardt Biosimilars Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Wockhardt Biosimilars Drug Product Portfolio
  42. 8.7.5 Wockhardt Recent Developments
  43. 8.8 United Laboratory
  44. 8.8.1 United Laboratory Company Information
  45. 8.8.2 United Laboratory Business Overview
  46. 8.8.3 United Laboratory Biosimilars Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 United Laboratory Biosimilars Drug Product Portfolio
  48. 8.8.5 United Laboratory Recent Developments
  49. 8.9 Tonghua Dongbao
  50. 8.9.1 Tonghua Dongbao Company Information
  51. 8.9.2 Tonghua Dongbao Business Overview
  52. 8.9.3 Tonghua Dongbao Biosimilars Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Tonghua Dongbao Biosimilars Drug Product Portfolio
  54. 8.9.5 Tonghua Dongbao Recent Developments
  55. 8.10 Shanghai Henlius
  56. 8.10.1 Shanghai Henlius Company Information
  57. 8.10.2 Shanghai Henlius Business Overview
  58. 8.10.3 Shanghai Henlius Biosimilars Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Shanghai Henlius Biosimilars Drug Product Portfolio
  60. 8.10.5 Shanghai Henlius Recent Developments
  61. 8.11 Luye Pharma
  62. 8.11.1 Luye Pharma Company Information
  63. 8.11.2 Luye Pharma Business Overview
  64. 8.11.3 Luye Pharma Biosimilars Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Luye Pharma Biosimilars Drug Product Portfolio
  66. 8.11.5 Luye Pharma Recent Developments
  67. 8.12 Jiangsu Hengrui
  68. 8.12.1 Jiangsu Hengrui Company Information
  69. 8.12.2 Jiangsu Hengrui Business Overview
  70. 8.12.3 Jiangsu Hengrui Biosimilars Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Jiangsu Hengrui Biosimilars Drug Product Portfolio
  72. 8.12.5 Jiangsu Hengrui Recent Developments
  73. 8.13 Innovent Biologics
  74. 8.13.1 Innovent Biologics Company Information
  75. 8.13.2 Innovent Biologics Business Overview
  76. 8.13.3 Innovent Biologics Biosimilars Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Innovent Biologics Biosimilars Drug Product Portfolio
  78. 8.13.5 Innovent Biologics Recent Developments
  79. 8.14 Geropharm
  80. 8.14.1 Geropharm Company Information
  81. 8.14.2 Geropharm Business Overview
  82. 8.14.3 Geropharm Biosimilars Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Geropharm Biosimilars Drug Product Portfolio
  84. 8.14.5 Geropharm Recent Developments
  85. 8.15 Gan&Lee
  86. 8.15.1 Gan&Lee Company Information
  87. 8.15.2 Gan&Lee Business Overview
  88. 8.15.3 Gan&Lee Biosimilars Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Gan&Lee Biosimilars Drug Product Portfolio
  90. 8.15.5 Gan&Lee Recent Developments
  91. 8.16 Dr Reddy’s
  92. 8.16.1 Dr Reddy’s Company Information
  93. 8.16.2 Dr Reddy’s Business Overview
  94. 8.16.3 Dr Reddy’s Biosimilars Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Dr Reddy’s Biosimilars Drug Product Portfolio
  96. 8.16.5 Dr Reddy’s Recent Developments
  97. 8.17 Celltrion
  98. 8.17.1 Celltrion Company Information
  99. 8.17.2 Celltrion Business Overview
  100. 8.17.3 Celltrion Biosimilars Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Celltrion Biosimilars Drug Product Portfolio
  102. 8.17.5 Celltrion Recent Developments
  103. 8.18 Celgen Biopharma
  104. 8.18.1 Celgen Biopharma Company Information
  105. 8.18.2 Celgen Biopharma Business Overview
  106. 8.18.3 Celgen Biopharma Biosimilars Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Celgen Biopharma Biosimilars Drug Product Portfolio
  108. 8.18.5 Celgen Biopharma Recent Developments
  109. 8.19 Bio-Thera
  110. 8.19.1 Bio-Thera Company Information
  111. 8.19.2 Bio-Thera Business Overview
  112. 8.19.3 Bio-Thera Biosimilars Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Bio-Thera Biosimilars Drug Product Portfolio
  114. 8.19.5 Bio-Thera Recent Developments
  115. 8.20 Biocon
  116. 8.20.1 Biocon Company Information
  117. 8.20.2 Biocon Business Overview
  118. 8.20.3 Biocon Biosimilars Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Biocon Biosimilars Drug Product Portfolio
  120. 8.20.5 Biocon Recent Developments
  121. 8.21 3SBIO
  122. 8.21.1 3SBIO Company Information
  123. 8.21.2 3SBIO Business Overview
  124. 8.21.3 3SBIO Biosimilars Drug Revenue and Gross Margin (2021-2026)
  125. 8.21.4 3SBIO Biosimilars Drug Product Portfolio
  126. 8.21.5 3SBIO Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst